• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

世界卫生组织和国际风湿病协会联盟关于类风湿关节炎临床试验中改善病情抗风湿药的核心终点指标。

World Health Organization and International League of Associations for Rheumatology core endpoints for symptom modifying antirheumatic drugs in rheumatoid arthritis clinical trials.

作者信息

Boers M, Tugwell P, Felson D T, van Riel P L, Kirwan J R, Edmonds J P, Smolen J S, Khaltaev N, Muirden K D

机构信息

Department of Internal Medicine/Rheumatology, University Hospital Maastricht, The Netherlands.

出版信息

J Rheumatol Suppl. 1994 Sep;41:86-9.

PMID:7799394
Abstract

The WHO/ILAR core set of endpoints for rheumatoid arthritis clinical trials signifies progress in a continuing worldwide effort. This core set includes the following measures: pain, patient global assessment, physical disability, swollen joints, tender joints, acute phase reactants, and physician global assessment; in studies of one or more years' duration, radiographs of joints should be performed.

摘要

世界卫生组织/国际实验动物科学委员会类风湿关节炎临床试验核心终点集标志着全球持续努力所取得的进展。该核心集包括以下指标：疼痛、患者整体评估、身体残疾状况、关节肿胀、关节压痛、急性期反应物以及医生整体评估；在为期一年或更长时间的研究中，应拍摄关节的X光片。

相似文献

1
World Health Organization and International League of Associations for Rheumatology core endpoints for symptom modifying antirheumatic drugs in rheumatoid arthritis clinical trials.世界卫生组织和国际风湿病协会联盟关于类风湿关节炎临床试验中改善病情抗风湿药的核心终点指标。
J Rheumatol Suppl. 1994 Sep;41:86-9.
2
Endpoints in rheumatoid arthritis.类风湿关节炎的终点指标
J Rheumatol Suppl. 1994 Oct;42:2-8.
3
Continuous indices of core data set measures in rheumatoid arthritis clinical trials: lower responses to placebo than seen with categorical responses with the American College of Rheumatology 20% criteria.类风湿关节炎临床试验核心数据集指标的连续性指标：与美国风湿病学会20%标准的分类反应相比，对安慰剂的反应更低。
Arthritis Rheum. 2005 Apr;52(4):1031-6. doi: 10.1002/art.20995.
4
An index of the three core data set patient questionnaire measures distinguishes efficacy of active treatment from that of placebo as effectively as the American College of Rheumatology 20% response criteria (ACR20) or the Disease Activity Score (DAS) in a rheumatoid arthritis clinical trial.在一项类风湿性关节炎临床试验中，由三个核心数据集患者问卷测量指标组成的一个指数，与美国风湿病学会20%反应标准（ACR20）或疾病活动评分（DAS）一样，能有效地区分积极治疗与安慰剂治疗的疗效。
Arthritis Rheum. 2003 Mar;48(3):625-30. doi: 10.1002/art.10824.
5
Should tetracycline treatment be used more extensively for rheumatoid arthritis? Metaanalysis demonstrates clinical benefit with reduction in disease activity.四环素治疗是否应更广泛地用于类风湿性关节炎？荟萃分析表明其对降低疾病活动度有临床益处。
J Rheumatol. 2003 Oct;30(10):2112-22.
6
Most patients receiving routine care for rheumatoid arthritis in 2001 did not meet inclusion criteria for most recent clinical trials or american college of rheumatology criteria for remission.2001年，大多数接受类风湿性关节炎常规治疗的患者不符合大多数近期临床试验的纳入标准或美国风湿病学会的缓解标准。
J Rheumatol. 2003 Jun;30(6):1138-46.
7
DC-ART: the concept.
J Rheumatol Suppl. 1994 Sep;41:3-5; discussion 5-7.
8
Clinical improvement as reflected in measures of function and health-related quality of life following treatment with leflunomide compared with methotrexate in patients with rheumatoid arthritis: sensitivity and relative efficiency to detect a treatment effect in a twelve-month, placebo-controlled trial. Leflunomide Rheumatoid Arthritis Investigators Group.与甲氨蝶呤相比，来氟米特治疗类风湿关节炎患者后，在功能和健康相关生活质量指标方面所反映出的临床改善：在一项为期12个月的安慰剂对照试验中检测治疗效果的敏感性和相对效率。来氟米特类风湿关节炎研究组。
Arthritis Rheum. 2000 Mar;43(3):506-14. doi: 10.1002/1529-0131(200003)43:3<506::AID-ANR5>3.0.CO;2-U.
9
A proposed revision to the ACR20: the hybrid measure of American College of Rheumatology response.美国风湿病学会（ACR）20%改善标准的一项拟议修订：美国风湿病学会反应的混合测量指标
Arthritis Rheum. 2007 Mar 15;57(2):193-202. doi: 10.1002/art.22552.
10
Comparison of rheumatoid arthritis clinical trial outcome measures: a simulation study.类风湿关节炎临床试验结果测量的比较：一项模拟研究。
Arthritis Rheum. 2003 Nov;48(11):3031-8. doi: 10.1002/art.11293.

引用本文的文献

1
Minimal important differences of measurement instruments used in rheumatoid arthritis: a scoping review.类风湿关节炎中使用的测量工具的最小重要差异：一项范围综述
BMC Rheumatol. 2025 Jul 8;9(1):83. doi: 10.1186/s41927-025-00524-9.
2
Patient Reported Outcome Measures for Rheumatoid Arthritis Disease Activity: Rasch measurement theory to identify items and domains.类风湿关节炎疾病活动度的患者报告结局测量：运用拉施测量理论确定条目和领域。
Rheumatology (Oxford). 2025 Sep 1;64(9):4902-4912. doi: 10.1093/rheumatology/keaf189.
3
RheuMetric Physician 0 to 10 Estimates of Inflammation, Damage, and Patient Distress at Initial Versus Follow-Up Visits in Contemporary Rheumatology Care.
在当代风湿病护理中，RheuMetric医生对初次就诊与随访时炎症、损伤及患者痛苦程度的0至10级评估。
ACR Open Rheumatol. 2025 Mar;7(3):e70010. doi: 10.1002/acr2.70010.
4
Physician estimate of inflammation global assessment in explaining variations in swollen joint counts in rheumatoid arthritis patients.医生对炎症的评估：类风湿关节炎患者肿胀关节计数变化的整体评估解释。
Rheumatol Adv Pract. 2024 Apr 27;8(2):rkae057. doi: 10.1093/rap/rkae057. eCollection 2024.
5
Impact of filgotinib on pain control in the phase 3 FINCH studies.在 3 期 FINCH 研究中，Filgotinib 对疼痛控制的影响。
RMD Open. 2024 Mar 12;10(1):e003839. doi: 10.1136/rmdopen-2023-003839.
6
Commonalities and differences in set-up and data collection across European spondyloarthritis registries - results from the EuroSpA collaboration.欧洲脊柱关节炎注册研究中的设置和数据收集的异同 - 来自 EuroSpA 合作的结果。
Arthritis Res Ther. 2023 Oct 19;25(1):205. doi: 10.1186/s13075-023-03184-7.
7
Effects of lifestyle physical activity and sedentary behaviour interventions on disease activity and patient- and clinician- important health outcomes in rheumatoid arthritis: a systematic review with meta-analysis.生活方式体育活动和久坐行为干预对类风湿性关节炎疾病活动及患者和临床医生重要健康结局的影响：一项荟萃分析的系统评价
BMC Rheumatol. 2023 Sep 6;7(1):27. doi: 10.1186/s41927-023-00352-9.
8
RheuMetric Quantitative 0 to 10 Physician Estimates of Inflammation, Damage, and Distress in Rheumatoid Arthritis: Validation Against Reference Measures.类风湿关节炎中炎症、损伤和痛苦的RheuMetric定量0至10分医生评估：与参考指标的验证
ACR Open Rheumatol. 2023 Oct;5(10):511-521. doi: 10.1002/acr2.11574. Epub 2023 Aug 22.
9
The use of PROMIS measures in clinical studies in patients with inflammatory arthritis: a systematic review.在炎症性关节炎患者的临床研究中使用 PROMIS 测量：系统评价。
Qual Life Res. 2023 Oct;32(10):2731-2749. doi: 10.1007/s11136-023-03422-0. Epub 2023 Apr 27.
10
Response to Treatment with Intravenous Golimumab or Infliximab in Rheumatoid Arthritis Patients: PROMIS Results from the Real-World Observational Phase 4 AWARE Study.类风湿关节炎患者接受静脉注射戈利木单抗或英夫利昔单抗治疗的反应：来自真实世界观察性4期AWARE研究的PROMIS结果
Rheumatol Ther. 2023 Jun;10(3):659-678. doi: 10.1007/s40744-023-00533-5. Epub 2023 Feb 23.